Eli Lilly: positive for eczema drug
(CercleFinance.com) - Eli Lilly announced that Baricitinib had achieved its primary endpoint in a Phase III experimental study in the treatment of severe atopic dermatitis, a form of eczema.
Added to corticosteroids, the kinase inhibitor led to a "significant" improvement in the severity of the disease, as measured by skin absent from lesions (or almost) after 16 weeks of treatment.
Eli Lilly says that patients with atopic dermatitis, a chronic disease, currently have few therapeutic leads, despite recent progress in research.
Baricitinib is already approved for the treatment of rheumatoid polyarthritis in about 60 countries. It is marketed in Europe under the trade name Olumiant.
The drug is being developed under a license agreement with Incyte.
Copyright (c) 2019 CercleFinance.com. All rights reserved.